Have changing pneumococcal vaccination programmes impacted disease in Ontario? (Q43719622)

26 November 2017

Have changing pneumococcal vaccination programmes impacted disease in Ontario? (English)

1 reference

26 November 2017

3

1 reference

26 November 2017

5

Jonathan B Gubbay

1 reference

PubMed ID

23597716

26 November 2017

Natasha Sarah Crowcroft

series ordinal

9

object named as

Natasha S Crowcroft

1 reference

26 November 2017

7

Don E Low

1 reference

26 November 2017

10

Shelley L Deeks

1 reference

26 November 2017

8

Karen Green

1 reference

26 November 2017

6

Wallis Rudnick

1 reference

26 November 2017

4

Dylan R Pillai

1 reference

26 November 2017

1

Gillian H Lim

1 reference

26 November 2017

2

Anne E Wormsbecker

1 reference

PubMed ID

23597716

26 November 2017

language of work or name

English

0 references

publication date

16 April 2013

1 reference

26 November 2017

1 reference

26 November 2017

31

1 reference

26 November 2017

24

1 reference

26 November 2017

2680-2685

1 reference

Bacterial meningitis in the United States in 1995. Active Surveillance Team

26 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

In vitro antimicrobial susceptibilities of Streptococcus pneumoniae clinical isolates obtained in Canada in 2002

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

The effect of routine vaccination on invasive pneumococcal infections in Canadian children, Immunization Monitoring Program, Active 2000–2007

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Epidemiology of invasive pneumococcal disease in BC during the introduction of conjugated pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Changing Epidemiology of Invasive Pneumococcal Disease in Canada, 1998–2007: Update from the Calgary‐Area Streptococcus pneumoniae Research (CASPER) Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Continued control of pneumococcal disease in the UK - the impact of vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Serotype 19A Is the most common serotype causing invasive pneumococcal infections in children.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Invasive pneumococcal infections in Canadian children, 1991-1998: implications for new vaccination strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control Immunization Monitoring Program, Active (IMPACT).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Epidemiology of invasive Streptococcus pneumoniae infections in the United States, 1995-1998: Opportunities for prevention in the conjugate vaccine era

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Serotypes and antimicrobial susceptibilities of invasive Streptococcus pneumoniae pre- and post-seven valent pneumococcal conjugate vaccine introduction in Alberta, Canada, 2000-2006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

EFFECTIVENESS OF PNEUMOCOCCAL CONJUGATE VACCINE IN GREATER VANCOUVER, CANADA: 2004???2005

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Indirect effects associated with widespread vaccination of infants with heptavalent pneumococcal conjugate vaccine (PCV7; Prevnar).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Decline in Invasive Pneumococcal Disease after the Introduction of Protein–Polysaccharide Conjugate Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

7-Valent pneumococcal conjugate vaccination in England and Wales: is it still beneficial despite high levels of serotype replacement?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

Efficacy of pneumococcal vaccination in adults: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.04.007

10.1016/J.VACCINE.2013.04.007

7 January 2021

Identifiers

DOI

1 reference

26 November 2017

1 reference

PubMed ID

23597716